U-Ploid, a venture-backed biotech company, has introduced its new platform designed to enhance the quality of older egg cells, a critical factor in increasing the success rates of in vitro fertilization (IVF) for women experiencing age-related infertility. The company’s technology aims to repair decades of accumulated damage in eggs, thereby improving their viability during IVF treatments.
Age-related fertility decline affects millions worldwide, placing significant emotional and financial burdens on individuals and families undergoing multiple unsuccessful IVF cycles. U-Ploid is developing a therapy intended to directly target the root cause of age-related female infertility by improving the health of older eggs.
“Our team is developing technology that directly targets the root cause of age-related female infertility,” said Dr. Chloe Charalambous, Co-founder and COO of U-Ploid Biotechnologies. “By improving the health of older eggs, we have the opportunity to help many people in their fertility journey.”
As more individuals choose to start families later in life, there is an increasing demand for advancements in fertility treatments. Egg cell quality remains a key factor influencing fertility outcomes. U-Ploid’s proprietary technology focuses on enhancing the viability of older eggs within an IVF cycle, offering a novel approach to fertility care.
“We are thrilled to introduce U-Ploid’s breakthrough technology, a significant step forward in addressing the global challenge of age-related infertility,” said Dr. Jordan Abdi, Co-founder and CEO of U-Ploid. “By improving egg quality, we aim to increase the chances of successful pregnancies through IVF.”
U-Ploid is collaborating with leading fertility clinics to bring this technology to patients. The company is preparing for clinical studies to validate the efficacy and safety of its platform and is working towards obtaining regulatory approvals for wider adoption.
